After observing deep, MRD-negative responses at their starting dose, Colonia Therapeutics unconventionally tested a lower dose level. This counter-intuitive strategy aims to identify the minimum effective dose, which is crucial for maximizing the safety profile (the therapeutic window) and improving commercial viability through lower manufacturing costs.

For patients with significant comorbidities like cardiovascular disease, proactively starting lenvatinib at a reduced dose (e.g., 14mg instead of 20mg) is a practical strategy to mitigate anticipated severe toxicities from the outset.

In the REJOYCE ovarian-1 trial for RDXD, the 5.6 mg/kg dose was selected to move forward over a 6.4 mg/kg dose that showed a higher response rate (57%). The lower dose had significantly fewer serious adverse events and a lower rate of interstitial lung disease (ILD), demonstrating a crucial trade-off where safety and tolerability outweigh peak efficacy in late-stage development.

Data on Enfortumab Vedotin suggests that for modern therapies, maintaining patients on treatment longer via a lower, more tolerable starting dose is more important than administering the maximum labeled dose upfront, a concept inherited from the cytotoxic chemotherapy era.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

Data shows that patients who permanently stopped ipilimumab due to immune-related side effects still had exceptionally good outcomes. This gives clinicians confidence to manage toxicity by discontinuing the CTLA-4 inhibitor portion of the regimen while continuing nivolumab, without fearing a loss of efficacy.

The REJOICE trial for an ADC in ovarian cancer exemplifies a critical trend: embedding multi-arm dose optimization studies. This approach identified a dose that maintained high response rates (57%) while significantly lowering rates of serious adverse events like ILD (from 6% to 3%), prioritizing patient safety.

A majority of patients on the lenvatinib/pembrolizumab regimen require dose reductions due to toxicity. Crucially, clinical trial data shows no significant change in progression-free survival for patients on lower doses, an important point for patient reassurance.

In the DESTINY-CRC02 trial, the lower 5.4 mg/kg dose of trastuzumab deruxtecan (TDXD) resulted in a higher response rate in colorectal cancer compared to the 6.4 mg/kg dose used in gastric cancer. This counter-intuitive finding suggests better tolerability led to longer treatment duration and superior outcomes.